EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk‐Stratification, and Treatment

Xavier Troussard iD, Elsa Maître iD, Jérôme Paillassa iD

American Journal of Hematology · 2026-12 · 101 (12) · 3010-3031

DOI: 10.1002/ajh.70441 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 15.09.2026. Verfasst von Xavier Troussard und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire Hématologie, CHU Côte de Nacre, Caen Cedex, France. Hauptthemen laut MEDLINE: Leukemia, Hairy Cell. Die Arbeit nennt 250 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disease Overview Hairy cell leukemia (HCL) and HCL‐like disorders, including HCL variant (HCL‐V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogeneous group of mature lymphoid B‐cell disorders characterized by the identification of hairy cells, a specific immunophenotypic and genetic profile, a different clinical course and the need for appropriate treatment. Diagnosis Diagnosis of HCL is based on morphological evidence of hairy cells, characteristic flow cytometric immunophenotype (CD11c, CD103, CD123, CD25) bone marrow trephine biopsy which makes it possible to specify the degree of tumoral bone marrow infiltration and presence of the Annexin A1 marker in immunohistochemistry, and presence of the BRAF V600E mutation. Risk Stratification Progression of patients with HCL is based on a large splenomegaly, leukocytosis, a high number of hairy cells in the peripheral blood and the unmutated ImmunoGlobulin HeaVy (IGHV) chain variable region gene mutational status. VH4‐34 positive HCL cases are associated with a poor prognosis, as well as the rare cases of HCL with TP53 mutations and HCL‐V. Treatment Patients should be treated only if HCL is symptomatic. Chemotherapy with purine analogs (PNAs) are indicated in first‐line HCL patients. The use of chemo‐immunotherapy combining cladribine (CDA) and rituximab (R) represents an increasingly used therapeutic approach. Management of relapsed/refractory disease is based on the use of BRAF inhibitors (BRAFi) plus R, MEK inhibitors (MEKi), Bruton Tyrosine Kinase inhibitors (BTKi) and/or Bcl‐2 inhibitors (Bcl‐2i). The optimal sequence of the different treatments remains to be determined.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Hairy CellHumansRisk AssessmentPrognosisImmunophenotypingMutation

Stichwörter der Autor:innen

hairy cell leukemia (HCL)hairy cell leukemia like disordershairy cell leukemia variant (HCL‐V)splenic diffuse red pulp lymphoma (SDRPL)

Autor:innen und Institutionen

  • Laboratoire Hématologie, CHU Côte de Nacre, Caen Cedex, France.
  • Service des Maladies du Sang, CHU Angers, Angers Cedex, France.

ORCID-Profile: Xavier Troussard, Elsa Maître, Jérôme Paillassa

Zitieren

APA

Troussard, X., Maître, E., & Paillassa, J. (2026). Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk‐Stratification, and Treatment. American Journal of Hematology, 101(12), 3010-3031. https://doi.org/10.1002/ajh.70441

Vancouver

Troussard X, Maître E, Paillassa J. Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk‐Stratification, and Treatment. American Journal of Hematology. 2026;101(12):3010-3031. doi:10.1002/ajh.70441

BibTeX
@article{Troussard2026,
  author = {Troussard, Xavier and Maître, Elsa and Paillassa, Jérôme},
  title = {Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk‐Stratification, and Treatment},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {12},
  pages = {3010--3031},
  doi = {10.1002/ajh.70441}
}
Kostenlos starten →